524804 Stock Overview
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Aurobindo Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,103.55 |
| 52 Week High | ₹1,177.00 |
| 52 Week Low | ₹581.50 |
| Beta | 0.58 |
| 1 Month Change | 4.83% |
| 3 Month Change | -4.08% |
| 1 Year Change | 78.76% |
| 3 Year Change | 14.13% |
| 5 Year Change | 38.32% |
| Change since IPO | 1,499.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524804 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.0% | 1.4% | 2.8% |
| 1Y | 78.8% | 57.2% | 46.6% |
Return vs Industry: 524804 exceeded the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: 524804 exceeded the Indian Market which returned 46.4% over the past year.
Price Volatility
| 524804 volatility | |
|---|---|
| 524804 Average Weekly Movement | 4.4% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: 524804 has not had significant price volatility in the past 3 months.
Volatility Over Time: 524804's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 23,451 | Kambam Reddy | www.aurobindo.com |
Aurobindo Pharma Limited engages in manufacturing of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, and internationally. It offers formulation in form of orals, injectables and over-the-counter drugs; and active pharmaceutical ingredients (API) for biosimilars, dermatology, respiratory, vaccines, and peptides, as well as oncology, hormones, and sterile products. The company also provides antiretroviral drugs for the people and children living with HIV; and AuroZymes, a biocatalysts product for use in the pharmaceutical and chemical industries.
Aurobindo Pharma Limited Fundamentals Summary
| 524804 fundamental statistics | |
|---|---|
| Market cap | ₹646.52b |
| Earnings (TTM) | ₹27.70b |
| Revenue (TTM) | ₹278.95b |
23.3x
P/E Ratio2.3x
P/S RatioIs 524804 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524804 income statement (TTM) | |
|---|---|
| Revenue | ₹278.95b |
| Cost of Revenue | ₹130.37b |
| Gross Profit | ₹148.58b |
| Other Expenses | ₹120.87b |
| Earnings | ₹27.70b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
| Earnings per share (EPS) | 47.28 |
| Gross Margin | 53.26% |
| Net Profit Margin | 9.93% |
| Debt/Equity Ratio | 23.6% |
How did 524804 perform over the long term?
See historical performance and comparison